Revolutionizing Heart Valve Care: Dr. Paul Sorajja Pioneers FDA‑Approved Treatment for Untreatable Mitral Annular Calcification

Groundbreaking Heart Valve Treatment Offers new Hope for inoperable Patients

Phoenix, Arizona – A revolutionary treatment for severe mitral annular calcification (MAC) is transforming cardiac care, giving patients previously deemed unsuitable for surgery a renewed chance at life. This advancement, spearheaded by Dr. Paul Sorajja at Banner – University Medical Center Phoenix, centers around a minimally invasive procedure utilizing the Tendyne mitral device.

What is Mitral Annular Calcification?

Mitral annular calcification, a condition where calcium builds up around the mitral valve in the heart, can lead to meaningful impairment of heart function. Traditionally, severe cases of MAC presented a formidable challenge for surgeons, frequently enough resulting in patients being considered “inoperable” due to the high risks associated with conventional open-heart surgery. According to the American Heart Association, approximately 1 in 10 people over the age of 75 have mitral annular calcification.

the Tendyne Device: A Minimally Invasive Solution

In 2016, Dr. Sorajja performed a historic first, implanting the Tendyne mitral device in a patient suffering from severe MAC. The procedure differs drastically from open-heart surgery. It involves accessing the heart through a small incision between the ribs,minimizing trauma and promoting a faster recovery. This innovative approach avoids the need for a lengthy sternotomy – the conventional opening of the chest – considerably reducing post-operative pain and rehabilitation time. the device effectively replaces the diseased valve, restoring proper blood flow.

Remarkable Clinical Trial Results

Extensive clinical trials, involving 103 patients, have demonstrated the effectiveness of the Tendyne device. The results revealed that approximately 90 percent of participants experienced substantial betterment in their symptoms and a noticeable increase in their ability to perform daily activities. Furthermore, the device proved highly accomplished in eliminating dangerous valve leakage, thereby reducing the risk of heart failure and other complications.

Comparing Traditional Surgery vs. Tendyne Device

Feature	Traditional Open-Heart Surgery	Tendyne Mitral Device (Minimally Invasive)
Incision Size	Large chest incision (sternotomy)	Small incision between the ribs
Recovery Time	Several weeks to months	Significantly faster, often weeks
Hospital Stay	Extended hospital stay	Shorter hospital stay
Risk of Complications	Higher risk of infection, bleeding, and other complications	Lower risk of complications

banner Health as a National Training Center

Following the recent FDA approval of the Tendyne device, Banner Health has emerged as a national leader in this advanced therapy. The institution now serves as a crucial training center, providing guidance and expertise to hospitals across the country seeking to adopt this life-changing technique.

“This is truly what modern medicine strives for,” stated Dr. Sorajja. “To be able to address conditions once thought untreatable and provide patients and their families with renewed hope is an unbelievable privilege.”

Disclaimer: This article provides general details and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

What are your thoughts on these advances in cardiac care? Do you know someone who might benefit from this innovative treatment?

Share this article with your network to spread awareness of this life-saving advancement!

What is the FDA-approved Sorajja procedure for treating mitral annular calcification?

Revolutionizing Heart Valve Care: Dr. Paul Sorajja Pioneers FDA‑Approved Treatment for Untreatable Mitral Annular Calcification

Mitral annular calcification (MAC), a common finding in aging populations and individuals with cardiovascular disease, has long presented a critically importent challenge to cardiologists. Traditionally considered untreatable without open-heart surgery, severe MAC can lead to mitral valve stenosis, regurgitation, and ultimately, heart failure. Though, a groundbreaking new approach spearheaded by Dr. Paul Sorajja is changing the landscape of heart valve care, offering a minimally invasive solution now backed by FDA approval.

Understanding Mitral Annular Calcification

MAC involves calcium deposits around the flexible ring (annulus) surrounding the mitral valve. While frequently enough asymptomatic, substantial calcification can stiffen the valve, hindering its proper function. This impacts the heart’s ability to efficiently pump blood, leading to symptoms like:

* Shortness of breath

* Fatigue

* Chest pain

* Irregular heartbeat (arrhythmia)

* Swelling in the ankles and feet

Diagnosis typically involves echocardiography, CT scans, and sometimes cardiac MRI to assess the extent and severity of the calcification. Historically, management focused on symptom control and monitoring. For severe cases, open-heart surgery – mitral valve replacement or repair – was the onyl definitive option.

the Sorajja Procedure: A New Paradigm in MAC Treatment

Dr. Sorajja, a renowned interventional cardiologist, developed a novel technique utilizing orbital atherectomy to address severe MAC. This procedure, now FDA-approved, employs a specialized device to precisely debulk the calcium deposits without requiring open-heart surgery.

Here’s how it works:

1. Access: A small incision is made, typically in the groin, to access a blood vessel.
2. Navigation: A catheter is guided through the vessel and into the heart, reaching the mitral valve.
3. Orbital Atherectomy: The orbital atherectomy device, featuring a high-speed rotating crown, is deployed to carefully and selectively remove the calcium deposits. This differs significantly from conventional balloon valvuloplasty,which can fracture the calcium and cause further damage.
4. Assessment: Following the debulking, the mitral valve function is reassessed using echocardiography to ensure optimal results.

Benefits of the FDA-Approved Treatment

the FDA approval of this procedure marks a pivotal moment for patients with severe MAC. The benefits are substantial:

* Minimally Invasive: Avoids the trauma and lengthy recovery associated with open-heart surgery.

* improved Valve function: Restores mitral valve flexibility and improves blood flow.

* Reduced Symptoms: Alleviates symptoms like shortness of breath, fatigue, and chest pain.

* Enhanced Quality of Life: Allows patients to return to their daily activities more quickly and with greater ease.

* Lower risk Profile: Compared to open-heart surgery, the procedure carries a lower risk of complications.

Patient Selection and Suitability

Not all patients with MAC are candidates for the Sorajja procedure. Ideal candidates typically exhibit:

* Severe MAC: Significant calcium deposits causing mitral valve dysfunction.

* Symptomatic Disease: Experiencing noticeable symptoms impacting their quality of life.

* High Surgical Risk: Individuals who are not suitable candidates for open-heart surgery due to age, comorbidities, or other factors.

* Specific Calcium Morphology: The procedure is most effective with certain patterns of calcium deposition. Careful imaging assessment is crucial.

A extensive evaluation by a specialized cardiac team is essential to determine individual suitability.

Real-world Impact: Case Studies & Early Outcomes

Early clinical data from centers pioneering the Sorajja procedure have been promising. Several case studies demonstrate significant improvements in mitral valve function and symptom relief. For example, a patient previously limited by severe shortness of breath and unable to walk even short distances experienced a dramatic improvement in their exercise capacity following the procedure.

Long-term follow-up studies are ongoing to assess the durability of the treatment and its impact on long-term cardiovascular outcomes. Initial results suggest a sustained benefit for appropriately selected patients.

The Future of Mitral Valve Care

Dr. Sorajja’s pioneering work represents a significant step forward in the treatment of mitral valve disease. This FDA-approved procedure offers a lifeline to patients previously considered untreatable, paving the way for a future where minimally invasive interventions play a more prominent role in heart valve care. Ongoing research and technological advancements will continue to refine these techniques and expand treatment options for an even wider range of patients with mitral annular calcification and other valve disorders.